Merck (MRK) Short-Term Debt issuances (2009 - 2026)

Merck's (MRK) quarterly Short-Term Debt issuances came in at $4.9 billion in Q2 2026, up 365.5% quarter-over-quarter from $1.1 billion in Q1 2026.

Analysis

Merck (MRK) Short-Term Debt issuances (2009 - 2026) Analysis & Trends

Merck (MRK) has reported Short-Term Debt issuances for 15 consecutive years, with $4.9 billion the latest figure, recorded in Q2 2026.

On a quarterly basis, Short-Term Debt issuances changed N/A year-over-year to $4.9 billion in Q2 2026; TTM through Jun 2026 was $6.1 billion, a N/A change from a year earlier, with the FY2021 full-year figure at $4.0 billion, up 56.38% from the prior year.
Short-Term Debt issuances was $4.9 billion for Q2 2026 at Merck, up from $1.1 billion in the prior quarter.
Over five years, Short-Term Debt issuances peaked at $4.9 billion in Q2 2026 and troughed at $63.0 million in Q3 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Short-Term Debt issuances (Qtr)
1	Johnson & Johnson	663.08 Bn	642.33 Bn	17.26 Bn	707.00 Mn
2	AbbVie	453.04 Bn	446.51 Bn	12.70 Bn	-
3	Merck	370.87 Bn	363.78 Bn	12.21 Bn	4.94 Bn
4	Novartis Ag	305.29 Bn	298.00 Bn	11.24 Bn	208.00 Mn
5	Pfizer	162.10 Bn	150.70 Bn	10.94 Bn	64.00 Mn
6	Sanofi	53.95 Bn	46.98 Bn	10.79 Bn	-
7	Revolution Medicines	45.00 Bn	45.00 Bn	-	-
8	BeOne Medicines	40.49 Bn	35.39 Bn	1.53 Bn	-
9	Incyte	25.47 Bn	20.94 Bn	1.57 Bn	-
10	United Therapeutics	20.81 Bn	18.15 Bn	683.80 Mn	-

Historic Data

Download Data